首页> 外文期刊>Вестник офтальмологии >An experimental substantiation for using the 'Semax' neuroprotector in the treatment of optic-nerve diseases
【24h】

An experimental substantiation for using the 'Semax' neuroprotector in the treatment of optic-nerve diseases

机译:用于使用“Semax”神经保护器治疗视神经疾病的实验证实实验证实

获取原文
获取原文并翻译 | 示例
           

摘要

In order to substantiate the feasibility of using the "Semax" neuroprotector in the treatment of optic-nerve diseases its pharmacokinetics in the intranasal administration was studied in experiments with rats; besides, the physical-and-chemical properties of Semax mobility in the electric field. A series of experiments, involving a tritium-marked "Semax", showed that the peptide actively penetrates into the brain and eyes of experimental animals after its intranasal administration. It was established, within a study aimed at determining the electrophoretic activity and stability of "Semax" in the electric field, that the preparation does not disintegrate in the electric field, it posses the electrophoretic mobility and moves, in the electric field, from plus to minus; therefore, the "Semax" solution must be fed from anode while making the electrophoresis procedure.
机译:为了证实使用“Semax”神经保护物在治疗视神经疾病中,其在大鼠实验中研究了鼻内给药中的药代动力学; 此外,电场中Semax迁移率的物理化学性质。 一系列涉及氚标记的“Semax”的实验表明,肽在其鼻内给药后主动地渗透到实验动物的脑中和眼睛中。 在一项研究中建立,旨在确定电场中“Semax”的电泳活性和稳定性,即制剂在电场中没有崩解,它可以在电场中具有电泳迁移率和移动。 减去; 因此,在制造电泳过程的同时,必须从阳极馈送“Semax”溶液。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号